Clinical trials: Stroke Assessment
Post-Stroke Spasticity, Cerebrovascular Accident
Study of GSK1358820 In Patients With Post-Stroke Lower Limb Spasticity
This is a study to confirm the superior efficacy of GSK1358820 over placebo in patients with equinus deformity associated with post-stroke lower limb spasticity using the Modified Ashworth Scale (MAS) ankle score.
- Trial name
- NCT00460655
- Testing
- GSK1358820
- Where
- 20 sites in Japan
- Volunteers
- 120 people
- Sponsor
- GlaxoSmithKline
Stroke, Gait Disorders, Neurologic
FeetMe® Monitor: Alternative for the Evaluation of Gait Speed After Stroke
The aim of this study is to validate a smart insoles system in comparison to the gold-standard GaitRite for a pathologic gait. The device evaluate gait parameters in real time thanks to an embedded algorithm based on the…
- Trial name
- NCT04266743
- Testing
- FeetMe Monitor
- Where
- France
- Volunteers
- 30 people
- Sponsor
- FeetMe
Healthy
Safety,Tolerability, and Pharmacokinetic of KPCXM18 for Injection
to assess the safety,Tolerability, and pharmacokinetic of KPCXM18 for injection in healthy subjects
- Trial name
- NCT04629287
- Testing
- KPCXM18
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Kunming Pharmaceuticals, Inc.
Stroke
The Evaluation of Safety, Tolerability and Pharmacokinetics of Stroke Targeting Drug in Healthy Volunteers
The purpose of this study in to evaluate safety, tolerability, pharmacokinetics of JPI-289 in healthy male subjects.
- Trial name
- JPI-289 (NCT01983358)
- Testing
- JPI-289
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Brain Ischemia, Stroke
Effects Of DP-b99 On Neurological Function In Subjects With Acute Ischemic Hemispheric Stroke
This study will examine if DP-b99 can improve neurological function (for example strength and coordination) in the 3 months after an acute stroke
- Conditions
- Brain Ischemia, Stroke, Cerebrovascular Disorders
- Trial name
- NCT00190047
- Testing
- DP-b99
- Where
- 22 sites in Germany, Israel
- Volunteers
- 150 people
- Sponsor
- D-Pharm Ltd.
Stroke
Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation
The purpose of this study is to establish the safety and effectiveness of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, including the post-implant medication regimen, for subjects with non-valvular atrial…
- Trial name
- ASAP-TOO (NCT02928497)
- Testing
- WATCHMAN LAAC Device Implant, Single Antiplatelet Therapy or No Therapy (Control)
- Where
- 92 sites in United States, Belgium and 7 more
- Volunteers
- 481 people
- Sponsor
- Boston Scientific Corporation
Post-Ischemic Stroke
A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.
The objective of this study is to determine the effect of two dose strengths of dalfampridine-Extended Release (ER) tablets, taken twice daily for 12 weeks, on stable walking deficits in subjects with post-ischemic stroke.
- Trial name
- MILESTONE℠ (NCT02271217)
- Testing
- dalfampridine-ER 7.5mg, dalfampridine-ER 10mg
- Where
- 74 sites in United States, Canada
- Volunteers
- 377 people
- Sponsor
- Acorda Therapeutics
Stroke, Stroke, Acute
Safety Evaluation of the ReWalk ReStore Device in Subjects With Mobility Impairments Due to Stroke
A multi-site, interventional, non-comparative, single-arm trial to evaluate the safety of the ReWalk ReStore device in subjects with hemiplegia/hemiparesis due to ischemic or hemorrhagic stroke.
- Conditions
- Stroke, Stroke, Acute, Stroke Hemorrhagic, Hemiparesis
- Trial name
- NCT03499210
- Testing
- ReWalk ReStore device
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- ReWalk Robotics, Inc.
Acute Ischemic Stroke
A Randomized Placebo-controlled Multicenter Trial to Evaluate the Efficacy and Safety of JTR-161, Allogeneic Human Dental Pulp Stem Cell, in Patients With Acute Ischemic stRoke (J-REPAIR)
The objective of this study is to evaluate the safety and efficacy of a single intravenous administration of JTR-161 (allogeneic stem cell product derived from the dental pulp of healthy adult humans) to patients with acute…
- Trial name
- J-REPAIR (NCT04608838)
- Testing
- JTR-161
- Where
- Japan
- Volunteers
- 79 people
- Sponsor
- Teijin Pharma Limited
Aspiration, Acute Ischemic Stroke
Safety and Efficacy of Intracranial Thrombus Aspiration Catheter in the Treatment of Acute Large-vessel Occlusive Stroke
A prospective, multicenter, single-arm objective performance criteria trial to investigate the safety and efficacy of SINOMED ADPAT for Recanalization Therapy in acute large-vessel occlusive stroke.
- Conditions
- Aspiration, Acute Ischemic Stroke, Large-vessel Occlusion
- Trial name
- NCT05101668
- Testing
- Intracranial Thrombosis Aspiration Catheter
- Where
- 6 sites in China
- Volunteers
- 26 people
- Sponsor
- Sinomed Neurovita Technology Inc.
Acute Ischemic Stroke
A Study of TAK-755 in Adults With Acute Ischemic Stroke
Acute ischemic stroke (AIS) is a medical emergency that happens because of a sudden stop of blood flow to a part of the brain. This happens when a blood clot forms within the vessel (known as thrombotic occlusion) or a clot…
- Trial name
- NCT07392450
- Testing
- TAK-755
- Where
- 60 sites in United States, Belgium and 8 more
- Volunteers
- 222 people
- Sponsor
- Takeda
Hypertension, Stroke
A Blood Pressure Regulation and Stroke Risk Evaluation Study in Hypertensive Patients Treated With Eprosartan
The primary objective of the study is to evaluate the proportion of hypertensive patients who achieve regulation of their blood pressure (BP) levels according to the European Society of Cardiology / European School of Haematology…
- Trial name
- NCT01562613
- Where
- 84 sites in Greece
- Volunteers
- 533 people
- Sponsor
- Abbott
Ischemic Stroke
DNS-3379 vs. Placebo in Stroke Rehabilitation
This is a randomized, double-blind, placebo-controlled parallel group outpatient 42-day treatment study that will utilize standard stroke rehabilitation outcome measures to evaluate the effect of DNS-3379 on upper extremity motor…
- Trial name
- SPIRIT (NCT03254160)
- Testing
- DNS-3379
- Where
- 16 sites in Australia, New Zealand
- Volunteers
- 1 people
- Sponsor
- Dart NeuroScience, LLC
Traumatic Brain Injury, Stroke
Safety Study of RP-1127 (Glyburide for Injection) in Healthy Volunteers
The primary objective of this study is to evaluate the safety and tolerability of different dose levels of glyburide for injection, administered as a bolus dose followed by a 3-day continuous infusion.
- Trial name
- NCT01132703
- Testing
- Glyburide for Injection
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Biogen
Atherosclerosis, Ischemia
Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)
The study is designed to determine whether vorapaxar, when added to the existing standard of care (SOC) for preventing heart attack and stroke (eg, aspirin, clopidogrel) in participants with a known history of atherosclerosis…
- Conditions
- Atherosclerosis, Ischemia, Myocardial Infarction, Cerebrovascular Accident
- Trial name
- NCT00526474
- Testing
- Vorapaxar
- Volunteers
- 26,449 people
- Sponsor
- Merck Sharp & Dohme LLC
Stroke
Safety and Tolerability of BIII 890 in Patients With Acute Ischemic Stroke
The objective of this study is to assess the safety, tolerability and pharmacokinetic characteristics of BIII 890 after intravenous infusion in acute ischemic stroke patients.
- Trial name
- NCT02251197
- Testing
- BIII 890 CL
- Volunteers
- 97 people
- Sponsor
- Boehringer Ingelheim
Stroke
A Clinical Trial to Assess the Acute Safety and Functional Outcome and Recovery After STROKE: The FIRST Trial
Current literature has only limited information on the natural history of acute ischemic stroke from large vessel occlusion in a stroke cohort who presents within 8 hours from symptom onset, particularly on 90 day functional…
- Trial name
- FIRST (NCT01092819)
- Testing
- Current standard of care for acute ischemic stroke other than IV rtPA or other IA therapies
- Where
- 3 sites in United States, China
- Volunteers
- 150 people
- Sponsor
- Penumbra Inc.
Acute Ischemic Stroke
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
This study is open to adults who had an acute stroke caused by a clot blocking a blood vessel in the brain (acute ischemic stroke).
- Trial name
- TENACITY (NCT07361302)
- Testing
- Tenecteplase, Standard of care treatment
- Where
- 257 sites in Argentina, Australia and 14 more
- Volunteers
- 1,325 people
- Sponsor
- Boehringer Ingelheim
Cerebrovascular Accident
Anti-MAG First Administration to Human
GSK249320 is a monoclonal antibody directed against myelin associated glycoprotein (MAG), a protein that inhibits axonal regeneration.
- Trial name
- NCT00622609
- Testing
- GSK249320A
- Where
- 2 sites in United States, Australia
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acute Ischemic Stroke AIS
A Phase II/III Clinical Study of SIM0811 in the Treatment of Acute Ischemic Stroke
The study will evaluate the efficacy and safety of SIM0811 in participants with acute ischemic stroke who are present within 4.5 to 24 hours since last known well. The main questions it aims to answer are: 1.
- Trial name
- NCT07903701
- Testing
- SIM0811 Dose Level A (Phase II), SIM0811 Dose Level B (Phase II), SIM0811 Dose Level C (Phase II)
- Volunteers
- 1,092 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.